Trials / Withdrawn
WithdrawnNCT03780166
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
A Phase 2 Dose-Escalation Study of the Safety and Tolerability of INCB050465 in Participants With Pemphigus Vulgaris
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of parsaclisib in participants with mild to moderate pemphigus vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Parsaclisib | Parsaclisib administered orally once daily at the cohort-specified dose level. |
Timeline
- Start date
- 2019-03-01
- Primary completion
- 2020-11-01
- Completion
- 2020-11-01
- First posted
- 2018-12-19
- Last updated
- 2019-09-13
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03780166. Inclusion in this directory is not an endorsement.